Financial statements are reported in AUD. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
IMMP — Immutep Limited
A$ 5.14
A$ -0.27 (-4.92%)
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Market Cap
A$ 37.85M
Forward P/E
-1.1x
52-Week Range
N/A
IMMP Price History
Revenue vs. Net Income
A$ 24.2M
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
-A$ 55.6M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-114.7%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
3.8x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.4%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+1921.6%
Dilution · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
